Stock Analysis
TG Therapeutics, Inc. (TGTX) Stock Analysis
TG Therapeutics, Inc. (TGTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
TG Therapeutics, Inc. (TGTX) currently has an AIQ Score of 76/100, indicating a bullish setup. Momentum is the strongest factor at 93/100. Risk is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TGTX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $64.51 |
| AIQ Score | 76/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $9.08B |
| P/E Ratio (TTM) | 86.6 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.39 |
| Revenue (Q3 FY2026) | $259.94M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.68 |
| Volume | 1.1M |
| 52-week range | $26.76-$68.03 |
| RSI 14 | 65.39 |
| 50-Day SMA | $56.69 |
| 200-Day SMA | $45.38 |
| Analyst Price Target | — |
| Next Earnings | Feb 25, 2027 |
TGTXTG Therapeutics, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum93
- Value65
- Quality69
- Risk resilience63
- Sentiment—
TGTX Stock Analysis Summary
TG Therapeutics, Inc. (TGTX) currently has an AIQ Score of 76/100, indicating a bullish setup. Momentum is the strongest factor at 93/100. Risk resilience is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, TGTX has AIQ Score of 76/100 with Momentum base of 93/100 and fading Risk resilience at 63/100. Wait for component alignment before adding exposure.
Momentum (93/100) leads while Risk resilience (63/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.08% stock move · TGTX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TGTX Bullish or Bearish Right Now?
TGTX currently has a bullish overall setup. Momentum is the strongest factor at 93/100, while Risk Resilience is weakest at 63/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 69/100.
- - Momentum is constructive at 93/100.
- - Price is +13.78% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (36 vs 2).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
TGTX's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 8 neutral, and 2 sell votes. TGTX's 14-day RSI is 65.39, which places the stock in a constructive momentum range. TGTX's beta is 0.68, indicating lower market sensitivity than the broad market.
What Changed in TGTX?
The largest recent change in TGTX is Quality moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the TGTX Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TGTX Decision Framework
Public evidence layers, setup checks, and risk context for TG Therapeutics, Inc..
TG Therapeutics, Inc. (TGTX) Stock Analysis
TG Therapeutics, Inc. has an AIQ Score of 76/100 in a Bullish regime. Momentum is strongest at 93/100. Beta is 0.68, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TGTX is in a Bullish AIQ regime with score 76/100. |
| Signal Conflict | The primary conflict is that momentum leads at 93/100 while risk lags at 63/100. |
| Factor Evidence | Momentum 93/100 · Value 65/100 · Quality 69/100 · Risk 63/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 93/100.
Momentum is 93/100 and RSI (14) is 65.4.
TGTX is in a Bullish regime at 76/100.
Risk factor is 63/100 with beta 0.68 and annual volatility 46.06%.
Current conflict: momentum leads at 93/100 while risk lags at 63/100.
TGTX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TGTX Fundamentals
TGTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TGTX Technical Analysis
TGTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TGTX Stock Catalysts
Track TGTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TGTX Dividend Analysis
TGTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TGTX Financial Data
TGTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TGTX Risk Analysis
TGTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TGTX Stock News
TGTX stock news, market tone, recent headlines, and catalyst context.
TGTX vs Biotechnology Peers
Current peer cohort: TGTX · TNGX · TRVI · TSHA · TVTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TGTX Current stock | 76/100 | 65/100 | 93/100 | 63/100 | 1.74 | 46.06% | Current |
| TNGX Tango Therapeutics, Inc. | 61/100 | — | 60/100 | 38/100 | 1.61 | 101.07% | TGTX vs TNGX |
| TRVI Trevi Therapeutics, Inc. | 63/100 | — | 52/100 | 51/100 | 0.52 | 59.27% | TGTX vs TRVI |
| TSHA Taysha Gene Therapies, Inc. | 35/100 | — | 32/100 | 37/100 | 0.32 | 70.69% | TGTX vs TSHA |
| TVTX Travere Therapeutics, Inc. | 64/100 | 69/100 | 67/100 | 55/100 | 0.87 | 62.28% | TGTX vs TVTX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for TGTX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TGTX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TGTX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TGTX Stock FAQ
What is TGTX stock price today?
TG Therapeutics, Inc.'s current stock price is $64.51. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TGTX bullish or bearish right now?
TGTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TGTX's market cap?
TGTX's market cap is $9.08B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TGTX's current P/E ratio?
TGTX's current P/E ratio is 86.6 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TGTX's RSI?
TGTX's 14-day RSI is 65.39 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TGTX above its 50-day and 200-day moving averages?
TGTX is 13.78% from its 50-day SMA and 42.16% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TGTX's next earnings date?
TGTX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TGTX pay a dividend?
TGTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.